
The study investigated the potential of gene expression profiles as biomarkers for therapy in a multiethnic UK cohort of systemic lupus erythematosus (SLE) patients who were refractory to standard therapy. It evaluated the baseline expression levels of transcripts associated with clinical features of SLE and measured responses to rituximab at 6 months from treatment start. The results suggest that ancestry, disease activity, and transcriptional signatures could assist in predicting the effectiveness of B cell depletion therapies. Ancestry appeared central to the immunologic and clinical heterogeneity in SLE, with responses to rituximab varying between different ancestral groups.
Like
Save
Share